Expert consensus on ensartinib in the treatment of anaplastic lymphoma kinase-positive non-small cell lung cancer.
10.3760/cma.j.cn112152-20220113-00033
- Author:
Li ZHANG
1
;
Yun Peng YANG
1
Author Information
1. Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou 510060.
- Collective Name:Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association;Expert Panel for Expert Consensus Development of Ensartinib in the Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer
- Publication Type:Journal Article
- Keywords:
Adverse events;
Anaplastic lymphoma kinase positive;
Anaplastic lymphoma kinase-tyrosine kinase inhibitor;
Expert consensus;
Lung neoplasms
- MeSH:
Anaplastic Lymphoma Kinase;
Carbazoles/adverse effects*;
Carcinoma, Non-Small-Cell Lung/pathology*;
Consensus;
Exanthema/drug therapy*;
Humans;
Lung Neoplasms/pathology*;
Piperazines;
Protein Kinase Inhibitors/adverse effects*;
Pyridazines
- From:
Chinese Journal of Oncology
2022;44(4):297-307
- CountryChina
- Language:Chinese
-
Abstract:
The mutation rate of anaplastic lymphoma kinase (ALK) in patients with non-small cell lung cancer is 3% to 7%. Due to its low mutation rate and better long-term survival compared with epidermal growth factor receptor-positive non-small cell lung cancer patients, therefore, it's called "diamond mutation". At present, there are three generations of ALK tyrosine kinase inhibitor (TKI) drugs in the world. The first-generation ALK-TKI drug approved in China is crizotinib, and the second-generation drugs are alectinib, ceritinib and ensartinib. Among them, ensartinib is an ALK-TKI domestically developed, and its efficacy is similar to that of alectinib. The main adverse event is transient rash, and compliance to ensartinib is better from the perspective of long-term survival of patients. The manifestation of rash caused by ensartinib is different from that of other ALK-TKI drugs. In order to facilitate clinical application and provide patients with more treatment options, under the guidance of the Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association, this article collects and summarizes the common adverse reactions of ensartinib. Based on the clinical practice, a clear adverse classification and specific treatment plan are formulated, in order to provide a corresponding reference for clinicians to make more comprehensive clinical decisions.
